Difference between revisions of "Colnot DR, et al. Cancer Immunol. Immunother. (2003) cited as Ref 554 in DOI: 10.1038/s41392-020-0110-5 (Q9817)"
Jump to navigation
Jump to search
(Added link to [sliswiki]: Colnot DR, et al. Cancer Immunol. Immunother. (2003) cited as Ref 554 in DOI: 10.1038/s41392-020-0110-5, #quickstatements; #temporary_batch_1589988087154) |
(Created claim: Page(s) (P105): 576-582, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Colnot DR | ||||||||||||||
| Property / First Author string: Colnot DR / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1007/s00262-003-0396-5 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 14627130 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2003
| ||||||||||||||
| Property / Publication Date: 2003 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Cancer Immunol. Immunother. | ||||||||||||||
| Property / Published In Name String: Cancer Immunol. Immunother. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 52 | ||||||||||||||
| Property / Volume: 52 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | Safety biodistribution pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck (English) | ||||||||||||||
| Property / title: Safety biodistribution pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 576-582 | ||||||||||||||
| Property / Page(s): 576-582 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Colnot DR, et al. Cancer Immunol. Immunother. (2003) cited as Ref 554 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Colnot DR
0 references
2003
0 references
Cancer Immunol. Immunother.
0 references
52
0 references
Safety biodistribution pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck (English)
0 references
576-582
0 references
